HUTCHMED (China) (HCM) investor relations material

Executive summary

• Achieved strong in-market sales growth for key oncology products, with ELUNATE® up 41%, SULANDA® up 45%, and FRUZAQLA® ex-US up ~70% year-over-year in H1 2026, driven by launches in 41 countries and expanded reimbursement.

• Two new product approvals (including Fruquintinib for RCC and savolitinib for GC) and three NDAs under review, with key Phase III readouts and global launches expected.

• Advanced innovation pipeline with multiple first-in-class ATTC assets in global phase I trials and a third asset entering the clinic in the second half, supported by AI-driven discovery.

• Net income was $16 million, down from $455 million in H1 2025, which included a one-time $416 million divestment gain.

• Maintained strong cash reserves of ~$1.4 billion to support R&D and global expansion.

Financial highlights

• Total group revenue was $278 million for the first half, flat year-over-year as oncology growth offset declines in low-margin segments.

• Oncology product revenue grew 23% to $121 million; total oncology/immunology revenue up 13% to $162 million.

• R&D expenses increased to $79 million from $72 million, reflecting investment in global phase I ATTC trials and AI technology.

• Cost of revenue as a percentage of oncology product revenue improved to 33% from 39% year-over-year.

• Adjusted group net cash inflow (non-GAAP, excluding financing) was $10.5 million.

Outlook and guidance

• Full-year 2026 oncology/immunology consolidated revenue guidance reiterated at $330–$450 million, with confidence in meeting or exceeding the range depending on milestone income and partnerships.

• Continued sales growth expected for FRUZAQLA® and preparation underway for the launch of Sovleplenib in hematology/immunology.

• Anticipate five ATTC programs in clinic by next year, with AI-driven discovery acceleration.